Last reviewed · How we verify

Aceclofenac and Esomeprazole — Competitive Intelligence Brief

Aceclofenac and Esomeprazole (Aceclofenac and Esomeprazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID) and proton pump inhibitor (PPI). Area: Gastroenterology.

phase 1 Nonsteroidal anti-inflammatory drug (NSAID) and proton pump inhibitor (PPI) COX-2 and H+/K+ ATPase Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Aceclofenac and Esomeprazole (Aceclofenac and Esomeprazole) — Dong Wha Pharmaceutical Co. Ltd.. Inhibits COX-2 and blocks the action of prostaglandins, thereby reducing inflammation and pain, and also inhibits the proton pump in the stomach, thereby reducing acid production.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Aceclofenac and Esomeprazole TARGET Aceclofenac and Esomeprazole Dong Wha Pharmaceutical Co. Ltd. phase 1 Nonsteroidal anti-inflammatory drug (NSAID) and proton pump inhibitor (PPI) COX-2 and H+/K+ ATPase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) and proton pump inhibitor (PPI) class)

  1. Dong Wha Pharmaceutical Co. Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aceclofenac and Esomeprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/aceclofenac-and-esomeprazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: